About PYRUKYND® (mitapivat) U.S. INDICATION PYRUKYND is a pyruvate kinase activator indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.

The Heathrow cyber disruption in September 2025 highlights how third-party vulnerabilities can ripple across national ...

It’s time for the FDA to re-evaluate its decision to authorise Q-Collar, say James Smoliga and Mu Yang A wearable “brain ...

SentinelOne is looking to get even more aggressive in its work with MSSPs and other channel partners in the coming year with ...

To safeguard enterprise data in hybrid cloud environments, organizations need to apply basic data security techniques such as ...

Positive high-level results from the Bax24 Phase III trial showed baxdrostat demonstrated a statistically significant and highly clinically meaningful reduction in ambulatory 24-hour average systolic ...

CrowdStrike (CRWD) and Okta Inc. (OKTA) are both at the forefront of the cybersecurity space, playing key roles in guarding organizations from extensive cyberattacks. While CrowdStrike specializes in ...

"Microsoft have identified that a code bug in the Microsoft Defender for Endpoint logic that fetches vulnerabilities for Dell devices is causing impact," the company said. "Your organization is ...

CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies ...